• (S)-(+)-Ibuprofen: COX Inhibitor Workflows and Research Insi

  2026-07-07

  (S)-(+)-Ibuprofen offers precise, selective COX inhibition, empowering inflammation and pain pathway research with consistent, high-purity results. This article delivers actionable experimental protocols, troubleshooting guidance, and translational insights for bench scientists leveraging APExBIO’s proven reagent.

• SP2509: Next-Generation LSD1 Antagonist Driving Epigenetic R

  2026-07-07

  Explore how SP2509, a potent Lysine-specific demethylase 1 antagonist, sets a new standard for acute myeloid leukemia and cancer epigenetics research. This article uniquely analyzes SP2509’s mechanistic selectivity, translational impact, and the implications of recent chromatin remodeling insights.

• Mildronate-Derived Lipidoids Enable Safer mRNA Vaccine Deliv

  2026-07-06

  The referenced ACS Nano study introduces mildronate-derived cationic lipidoids as a novel class of lipid nanoparticle components for mRNA vaccine delivery. This innovation achieves high delivery efficiency while significantly reducing inflammatory side effects, addressing a central barrier to the clinical translation of mRNA vaccines.

• Afatinib (BIBW 2992) Empowering Next-Gen Cancer Assembloids

  2026-07-06

  Afatinib (BIBW 2992) is redefining targeted therapy research by enabling high-fidelity EGFR, HER2, and HER4 pathway inhibition in advanced assembloid models. This guide covers experimental workflows, troubleshooting, and actionable optimization tips for leveraging Afatinib in physiologically relevant tumor–stroma studies.

• Nirmatrelvir (PF-07321332): Optimizing SARS-CoV-2 Inhibition

  2026-07-05

  Nirmatrelvir (PF-07321332) is a benchmark inhibitor for dissecting SARS-CoV-2 replication, enabling robust, reproducible antiviral research. This guide delivers stepwise protocols, troubleshooting insights, and strategic context for advanced COVID-19 therapeutics studies.

• Nutlin-3a as a Precision Tool for Dissecting p53-Dependent F

  2026-07-04

  Explore how Nutlin-3a, a leading MDM2 inhibitor, enables precise p53 pathway activation and advances the study of ferroptosis and apoptosis in cancer research. This article delivers unique, protocol-focused insights for experimental design.

• Dacomitinib (PF-00299804): Pan-HER Inhibition and Mitochondr

  2026-07-03

  Explore how Dacomitinib (PF-00299804) advances cancer research by combining irreversible pan-HER inhibition with insights into mitochondrial metabolic regulation. This article delivers a unique, application-focused analysis of Dacomitinib’s mechanistic depth, bridging receptor signaling, cell fate, and ferroptosis resistance.

• VE-821: ATR Kinase Inhibition Unveils New Horizons in DNA Re

  2026-07-03

  Explore how VE-821, a selective ATR kinase inhibitor, is transforming DNA repair pathway research and radiosensitization assays. This article delivers actionable insights, protocol guidance, and a unique analytical perspective not covered by existing content.

• EZ Cap™ Firefly Luciferase mRNA (5-moUTP): Evidence & Protoc

  2026-07-02

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) enables robust, low-immunogenicity bioluminescent reporter assays. Its Cap1 and 5-moU modifications enhance mRNA stability, translation, and immune evasion, facilitating sensitive applications in gene regulation and cell viability studies.

• Patient-Derived 3D Spheroids: Advanced Prostate Cancer Model

  2026-07-02

  This study introduces patient-derived 3D spheroid cultures from radical prostatectomy specimens as a translational model for organ-confined prostate cancer. By enabling extended culture viability and drug response testing, the model advances preclinical research and supports more physiologically relevant investigations of tumor biology and therapeutic efficacy.

• VX-745: Expanding Horizons in p38α MAPK Inhibitor Research

  2026-07-01

  Explore how VX-745, a potent p38α MAPK inhibitor, pioneers new assay strategies through dual-action kinase modulation. This article delivers a deep-dive into mechanistic insights, protocol optimization, and the impact of recent structural biology breakthroughs.

• Dual-Action Modulation of p38α MAPK: Inhibitor-Induced Depho

  2026-07-01

  The recent study by Stadnicki et al. elucidates how certain kinase inhibitors, including those targeting p38α MAP kinase, can simultaneously block kinase activity and accelerate dephosphorylation of the activation loop by phosphatase WIP1. This dual-action mechanism advances the conceptual framework for kinase inhibitor design and may open new avenues for increasing drug specificity in inflammatory disease research.

• QSHXO Mitigates MASLD via Autophagy Activation and Ferroptos

  2026-06-30

  This study elucidates how Qushi Huoxue ointment (QSHXO) ameliorates metabolic associated steatotic liver disease (MASLD) by concurrently activating autophagy and inhibiting ferroptosis in a murine model. The findings clarify mechanistic links between cell stress pathways and MASLD pathology, providing a foundation for future interventions targeting autophagy and the Nrf2 axis.

• Reserpine (N1867): Technical Guidance for Lab Research Workf

  2026-06-30

  Reserpine (SKU N1867) addresses reproducibility challenges in neurotransmitter depletion and antihypertensive mechanism research by providing a high-purity, well-characterized standard. It is not suitable for diagnostics or therapeutic use and requires strict adherence to solubility and storage protocols to maintain experimental integrity.

• Phenothiazines Enhance Macrophage Antibacterial Activity via

  2026-06-29

  The referenced study demonstrates that phenothiazine compounds, including promethazine hydrochloride, significantly augment the antibacterial activity of macrophages by inducing reactive oxygen species (ROS) and autophagy. This host-directed mechanism offers a promising alternative to traditional antibiotics, particularly in addressing intracellular pathogens and rising antimicrobial resistance.

16318 records 1/1088 page Next 12345 下5页 Last page